GT Biopharma (GTBP) Other Working Capital Changes (2022 - 2024)
GT Biopharma (GTBP) posted quarterly Other Working Capital Changes of -$28000.0 for Q1 2024, down 3.7% year-over-year from -$29076.9 in Q2 2023, and up 17.65% quarter-over-quarter from -$34000.0 in Q4 2023.
GT Biopharma (GTBP) Other Working Capital Changes (2022 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Other Working Capital Changes for 3 consecutive years, with -$28000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Other Working Capital Changes fell 3.7% year-over-year to -$28000.0; the TTM figure through Dec 2024 stood at -$90000.0 (up 22.41% YoY), while the FY2024 annual figure was -$58000.0, up 50.0% from the prior year.
- Other Working Capital Changes climbed to -$28000.0 in Q1 2024 per GTBP's latest filing, from -$34000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $123000.0 in Q3 2020 and bottomed at -$63000.0 in Q1 2020.
- Historically, Other Working Capital Changes has averaged $700.0 across 4 years, with a median of -$500.0 in 2019.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes sank 107.69% — and 2024, when it fell 3.7%.
- GT Biopharma's Other Working Capital Changes stood at -$24000.0 in 2022, then sank by 41.67% to -$34000.0 in 2023, then increased by 17.65% to -$28000.0 in 2024.
- Business Quant data shows GTBP's Other Working Capital Changes at -$28000.0 in Q1 2024, -$34000.0 in Q4 2023, and -$28000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -28,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -34,000.00 |
| Dec 31, 2023 | -34,000.00 |
| Dec 31, 2023 | -34,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Sep 30, 2022 | -25,000.00 |
| Sep 30, 2022 | -25,000.00 |